Amneal Pharmaceuticals, Inc. $AMRX Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC reduced its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 73.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 26,460 shares of the company’s stock after selling 72,669 shares during the period. SG Americas Securities LLC’s holdings in Amneal Pharmaceuticals were worth $265,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Rubric Capital Management LP grew its stake in Amneal Pharmaceuticals by 9.1% in the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock valued at $94,737,000 after acquiring an additional 974,355 shares during the period. Nantahala Capital Management LLC grew its position in shares of Amneal Pharmaceuticals by 14.7% in the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after purchasing an additional 558,877 shares during the period. BlackBarn Capital Partners LP increased its stake in shares of Amneal Pharmaceuticals by 19.6% during the second quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock worth $27,883,000 after purchasing an additional 564,916 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Amneal Pharmaceuticals by 2.5% during the 2nd quarter. Acadian Asset Management LLC now owns 2,662,524 shares of the company’s stock worth $21,525,000 after purchasing an additional 64,230 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in Amneal Pharmaceuticals by 187.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,150,041 shares of the company’s stock valued at $21,522,000 after buying an additional 1,401,190 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Performance

NASDAQ AMRX opened at $13.83 on Wednesday. The stock’s fifty day moving average is $12.69 and its two-hundred day moving average is $10.75. The firm has a market capitalization of $4.35 billion, a P/E ratio of 691.85 and a beta of 1.34. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.68 and a fifty-two week high of $13.99.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.12 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 185.60% and a net margin of 0.20%.The business had revenue of $784.51 million for the quarter. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. As a group, sell-side analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Wall Street Analysts Forecast Growth

AMRX has been the subject of several research reports. Barclays started coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 price objective for the company. Truist Financial set a $15.00 price target on Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $13.00 target price (up previously from $11.00) on shares of Amneal Pharmaceuticals in a report on Friday, October 31st. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $13.80.

Insider Activity at Amneal Pharmaceuticals

In related news, EVP Nikita Shah sold 131,856 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total value of $1,571,723.52. Following the completion of the transaction, the executive vice president directly owned 146,403 shares in the company, valued at approximately $1,745,123.76. This represents a 47.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ted C. Nark sold 50,000 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $11.72, for a total value of $586,000.00. Following the sale, the director directly owned 291,029 shares of the company’s stock, valued at approximately $3,410,859.88. This trade represents a 14.66% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 231,856 shares of company stock valued at $2,743,724. Corporate insiders own 17.45% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.